BioSpace News Archive

The Chief Executive Officer for BetterLife Pharma Inc., recently joined investor portal Proactive to discuss the successful trial of another interferon inhalation treatment for COVID-19 similar to BetterLife’s AP-003 product, what this trial means for BetterLife, and what advantages AP-003’s interferon alpha2b may have over interferon beta treatments.

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the launch of the RI.HIP NAVIGATION for total hip arthroplasty (THA).

Recently, the Chinese Institute of Food Science and Technology brought together experts in Beijing to evaluate the results of a collaborative R&D effort between Infinitus Company Ltd. and Hangzhou Hunter Biotechnology Co., Ltd., named the Application of Zebrafish Efficacy and Safety Rapid Evaluation System in Health Food.

Collaboration will include development of Thermo Fisher products and strategic manufacturing support [28-July-2020] WALTHAM, Mass. , July 28, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc., the world leader in serving science, and biotechnology company Lyell Immunopharma, are partnering to develop manufacturing processes designed to create more effective cell ther

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the appointment of Mr. Ivan Yifei Zhu as its Chief Commercial Officer, effective August 10, 2020 . Mr. Zhu will report directly to Dr. Ji

IsoPlexis partners with Neoline to extend sales of its single-cell proteomic analysis platform, IsoLight and IsoCode & CodePlex Chips, to the pharmaceutical and life science markets in China

NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces that during July 2020, the Company retired approximately $3.3 million of debt, strengthening the Company’s balance sheet.

July 28, 2020 12:00 UTC --Next-wave engineered protein company with pipeline of cytokine therapeutics developed in Versant’s Ridgeline Discovery Engine-- --First IL-2 development candidate shows superior properties to all known competitors-- --Industry veteran Sef Kurstjens joins as president and CEO--

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced that it has chosen its first U.S. clinical site for the Phase II trial of its lead drug LSALT peptide (Metablok).

American Screening, LLC, a premier domestic and international manufacturer and distributor of diagnostic products and essential medical supplies, is pleased to announce the addition of a COVID-19 IgG/IgM rapid test to its inventory.